Pluristem Therapeutics Inc (PSTI)

[FDApproved]

“Pluristem has a vast and dynamic program developing our PLX-R18 therapy as a treatment for ARS, which can potentially save many lives,” said Zami Aberman, Co-CEO and Chairman of Pluristem. “Receiving Orphan Drug Designation brings us one step closer to providing a next-generation medical countermeasure against ARS, which is especially important given today’s volatile political climate.”


https://www.econotimes.com/FDA-Grants-Pluristem-Orphan-Drug-Designation-for-Its-PLX-R18-Cell-Therapy-as-Treatment-for-Acute-Radiation-Syndrome-960035#